title: Phase1/-2 study of Pomalidomide in myelofibrosis.
authors.forename: Ruben A
authors.initials: RA
authors.lastname: Mesa
authors.forename: Animesh D
authors.initials: AD
authors.lastname: Pardanani
authors.forename: Kebede
authors.initials: K
authors.lastname: Hussein
authors.forename: Wenting
authors.initials: W
authors.lastname: Wu
authors.forename: Susan
authors.initials: S
authors.lastname: Schwager
authors.forename: Mark R
authors.initials: MR
authors.lastname: Litzow
authors.forename: William J
authors.initials: WJ
authors.lastname: Hogan
authors.forename: Ayalew
authors.initials: A
authors.lastname: Tefferi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D013792:Thalidomide; D011239:Prednisolone; C467566:pomalidomide